This research is about a contraceptive that is:
- Weekly: one tablet once a week
- Oral: swallowing the tablet
- Mifepristone as its name
- Easy: once a week and reminder via the app
- No 'normal hormones' from the pill or other contraceptives
And More?
- Almost anyone who menstruates (18 up to and including 35 years) can participate in the study
- Mifepristone 50 mg once a week is expected to be a safe and effective contraceptive, with few side effects
- It is expected that monthly blood loss will decrease significantly when using this contraceptive and may possibly stop completely
Are you interested in participating in this study? First fill out the questionnaire here to check if you are suitable to participate. At the end of the questions you will get a list of the participating hospitals and contact information.
At this moment Alkmaar/Den Helder (NoordWestZiekenhuis), Almelo (ZGT), Almere (Flevoziekenhuis), Amsterdam (Amsterdam UMC), Enschede (Medisch Spectrum Twente), Goes (Admiraal de Ruyter Ziekenhuis), Groningen (Martini Ziekenhuis), Leeuwarden (Frisius MC), Leiden (LUMC), Nijmegen (CWZ Nijmegen), Rotterdam (Franciscus Gasthuis), Utrecht (Diakonessenhuis) en Veldhoven (MMC Veldhoven) are open for enrollment.
In the coming weeks, Maastricht will also be open for enrollment. Updates and announcements will be posted on this website.
If you have questions you can also email: womenandmore@lumc.nl